For myhairline.ai, context is the difference between useful guidance and another anxiety spiral. Pattern, density, age, family history, and treatment tolerance all matter before anyone jumps to a product or procedure.
Cover image suggestion: A clean diagrammatic cross-section of a hair follicle showing miniaturization stages, no people, soft clinical lighting, anatomical illustration style.
Meta description: A working explanation of dihydrotestosterone, the androgen receptor, and how a single hormone reshapes the scalp over two decades, written for adults trying to understand what is actually happening to their hair.
Last March, a 28-year-old software developer named Kevin in Austin noticed his barber pausing mid-cut, tilting the mirror to show him a spot at the crown he’d never paid attention to. “I thought it was the lighting,” Kevin told me over email. “Then I took a photo with my phone flash at home, and it wasn’t the lighting. That one photo sent me down a six-hour rabbit hole.” His serum DHT came back at 62 ng/dL. His dermatologist told him what most dermatologists tell most men in their late twenties who show up with that mirror-photo dread: this is androgenetic alopecia, and the molecule at the center of it is dihydrotestosterone.
The first time most people encounter “DHT” is in a YouTube comment thread, usually paired with a finasteride box and a strong opinion. That’s a shame. Dihydrotestosterone is one of the better-studied molecules in human endocrinology, and the story of how it quietly remodels the human scalp over a decade or two is genuinely interesting once you peel away the marketing noise and the forum panic.
This piece is a working explanation of what DHT does, why the androgen receptor matters, how follicle miniaturization actually works, and how to think about your own situation without spiraling or getting sold something you don’t need.
The Molecule Itself
Dihydrotestosterone is a metabolite of testosterone. Inside specific tissues, the enzyme 5-alpha-reductase converts testosterone into DHT. Two isoforms matter for hair: type 1, which lives in the sebaceous glands and skin, and type 2, which concentrates in the scalp dermal papilla (and the prostate, which is how we ended up with finasteride in the first place, but more on that later).
Here’s the thing that makes DHT so central to this whole conversation: it binds the androgen receptor roughly three to five times more tightly than testosterone does. The androgen receptor sits inside the cell. When DHT clicks into place, the receptor migrates to the nucleus and changes which genes get transcribed.
For most tissues, this is a normal regulatory pathway. For the dermal papilla of a follicle that carries androgenetic alopecia susceptibility, the result is a programmed shrinking of the follicle across each successive growth cycle. Same hormone, different consequences depending on where in the body you look. It’s like water: essential in your garden, catastrophic in your basement.
How a Follicle Slowly Disappears
A healthy terminal hair follicle on the scalp cycles through anagen (growth), catagen (transition), and telogen (rest) over roughly two to seven years. Each cycle is supposed to produce a thick, pigmented shaft of similar caliber to the one before it.
In androgenetic alopecia, DHT signaling shortens anagen and forces the follicle to produce a slightly thinner shaft each cycle. Over years, the follicle progresses from terminal hair to indeterminate hair to vellus hair. The visual outcome is the recession and crown thinning most people recognize. Hamilton mapped those patterns in 1951; Norwood revised the classification in 1975 into the seven-stage system clinicians still reference today.
The downstream genes activated by the androgen receptor include several growth factor pathways. Transforming growth factor beta gets upregulated. Dickkopf-1 increases in some studies. IGF-1 signaling shifts. These downstream signals are what physically reduce the size of the dermal papilla and shorten the growth phase. The follicle doesn’t die, at least not right away. It shrinks, slowly, cycle by cycle, like a photocopier gradually running out of toner.
The Donor Zone Paradox (and Why Transplants Work)
The temporal and occipital scalp follicles, the donor zone harvested in transplant procedures, are essentially DHT-resistant in androgenetic alopecia. The reason isn’t that DHT is absent there. It’s differential expression of the androgen receptor and of 5-alpha-reductase across scalp regions.
This is the molecular basis of every hair transplant ever performed. Surgeons relocate follicles from a DHT-insensitive zone into a DHT-sensitive zone, and the relocated follicles continue to behave as donor tissue. They keep growing because the genetic program inside the follicle didn’t change when it moved neighborhoods.
For readers who want a full visual mapping of how androgenetic alopecia progresses across the seven stages, Myhairline.ai maintains a detailed reference pairing each Norwood stage with the typical follicular pattern beneath it.
Genetics: More Complex Than “Check Your Mom’s Dad”
Androgenetic alopecia is polygenic. The largest contribution comes from variants near the androgen receptor gene on the X chromosome, which is why the maternal side of the family gets cited as a useful predictor. But it’s not the whole story, not even close. Genome-wide association studies published in JAAD and elsewhere have identified more than 200 loci associated with male pattern baldness risk.
In practice, that means two brothers with the same mother can have meaningfully different outcomes. A clean maternal line doesn’t guarantee retention. The system is probabilistic. Kevin’s older brother, for instance, has a full head of hair at 34. Same parents, different draw from the genetic deck.
Pharmacology That Actually Follows the Biology
Once you understand the DHT pathway, the treatment landscape becomes legible instead of confusing.
Finasteride is a competitive inhibitor of type 2 5-alpha-reductase. It lowers serum and scalp DHT levels by roughly 60 to 70 percent at the standard 1 mg oral dose. (It was originally developed for benign prostatic hyperplasia at 5 mg; the hair dose is a fraction of that.) Dutasteride inhibits both type 1 and type 2 isoforms and produces a deeper suppression, around 90 percent. Both work upstream, reducing the substrate the androgen receptor sees.
Minoxidil works through a completely different mechanism. It’s a potassium channel opener and a vasodilator. In the scalp, it appears to extend anagen and increase follicle size through effects independent of androgen signaling. That’s why combination therapy with a 5-alpha-reductase inhibitor and minoxidil is the standard pharmacologic approach in published guidelines from the American Academy of Dermatology.
Topical anti-androgens, ketoconazole shampoo, and newer compounds targeting prostaglandin pathways get layered onto this core in various protocols. None of them are cures. The condition is genetic and lifelong. Stopping treatment generally returns the follicle to its previous trajectory within twelve months.
The boring truth: the strongest evidence for slowing progression remains oral finasteride 1 mg daily and topical minoxidil 5 percent twice daily, in combination, with the understanding that response is partial and variable. Hair transplantation is well-established for restoring density in selected stages, with FUE and FUT both having defensible track records when performed by qualified surgeons. PRP, low-level laser therapy, and microneedling have growing but more variable evidence bases.
What the evidence does not support is the long list of supplements, scalp serums, and lifestyle hacks dominating social media. They’re not all useless, but the marginal effect is small relative to the pharmacologic baseline. I’d go further: the energy spent researching rosemary oil protocols would, for most men, be better spent making a dermatology appointment.
Where AI Image Classification Fits (and Where It Doesn’t)
Visual classification of androgenetic alopecia stage from a photograph is something deep learning models do reasonably well. The Norwood scale is essentially a categorical pattern recognition problem, and there’s enough training data to support it. Models published in JAMA Dermatology in 2023 reported agreement with board-certified dermatologists in the 85 to 92 percent range on cropped scalp images.
That’s useful for self-orientation. It is not a diagnostic substitute. An AI cannot palpate the scalp, ask about timeline and family history, rule out telogen effluvium or alopecia areata, or evaluate scarring patterns that suggest cicatricial alopecia rather than androgenetic loss. A reading of “Norwood 3” from a phone photo is a hypothesis, not a prescription. Treatment decisions need clinical assessment.
Three Honest Checkpoints
If you’re reading this because you’re worried about your own hair, three things worth considering:
Timeline. Androgenetic alopecia is slow. Loss over weeks suggests telogen effluvium, alopecia areata, or another acute process, and that deserves a dermatology visit, not a hair-loss subreddit. Loss measured in years fits the androgenetic pattern.
Pattern. Bitemporal recession with crown thinning, both progressing on the same person, fits androgenetic alopecia in men. A diffuse pattern with preserved frontal hairline can be female pattern hair loss or thyroid-driven shedding. Scarring or patches of complete loss need an in-person assessment.
Family history. Mother’s side helps, but the polygenic background means individual outcomes vary. Use it as a data point, not a verdict.
Setting the Right Goal
The realistic outcome of well-executed medical therapy for androgenetic alopecia is to slow progression and gain back some density. Not to restore the hairline you had at 18. People who frame the goal as preservation tend to be far more satisfied with results than people who frame it as regrowth, because the underlying biology is friendlier to the first goal than to the second.
For most readers, the right sequence is: understand the pattern, get a baseline classification, talk to a board-certified dermatologist, and decide whether the cost and tradeoffs of long-term pharmacologic therapy are worth it for you. The AI tool is a starting point, not a destination.
The hormone science here is settled. What you choose to do with it is personal.
Frequently Asked Questions
Does DHT cause hair loss everywhere on the body? No. DHT actually promotes hair growth in areas like the beard, chest, and arms. Its miniaturizing effect is specific to genetically susceptible scalp follicles, which is why someone can be losing hair on their crown while growing a thicker beard at the same time.
Can you have high DHT and not lose your hair? Yes. DHT levels alone don’t determine hair loss. The sensitivity of your androgen receptors, governed by genetics, is what matters. Some men with high circulating DHT retain a full head of hair because their scalp follicles have low receptor density or expression.
Does lowering DHT with finasteride affect muscle growth or testosterone levels? Finasteride blocks conversion of testosterone to DHT, which typically results in a slight increase in circulating testosterone (roughly 10 to 15 percent). Most clinical data do not show significant effects on muscle mass at the 1 mg dose, though individual experiences vary and should be discussed with a physician.
Is female pattern hair loss also driven by DHT? The role of androgens in female pattern hair loss is less clear-cut than in men. Some women show androgen-mediated miniaturization, but many do not have elevated androgen levels. Female pattern hair loss involves additional factors and its pathophysiology is still being fully mapped.
How quickly does miniaturization progress? It varies widely. Some men notice visible thinning within a few years of onset; others progress very slowly over decades. Progression rate depends on genetic susceptibility, hormonal profile, and age of onset. Earlier onset (teens or early twenties) sometimes, though not always, correlates with more aggressive progression.
If I stop taking finasteride, will my hair fall out faster than if I’d never started? No. Stopping finasteride returns DHT levels to baseline, and miniaturization resumes at roughly the pre-treatment trajectory. You don’t “overshoot” or lose hair faster as a rebound effect. You lose the gains you made, typically within 6 to 12 months.
Are there blood tests I should get before starting treatment? A baseline hormonal panel (testosterone, free testosterone, DHT) and a thyroid panel can help rule out other causes of hair loss and give your dermatologist a clearer picture. These are not strictly required for a clinical diagnosis of androgenetic alopecia, but they’re useful context, especially for younger patients or atypical presentations.
